Art. -Nr.: HY-B0968A

Trimetazidine

19 Cited Publications

Kundenbewertung

Based on 19 publication(s) in Google Scholar

Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.84%
CAS. Nr.: 5011-34-7
Formel: C₁₄H₂₂N₂O₃
Molecular Weight:266.34

Speicherung:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Trimetazidine Chemical Structure

CAS. Nr.: 5011-34-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (19)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 75 nM (long chain 3-ketoyl coenzyme A thiolase)^[2]
β-oxidation^[2]
Autophagy^[3]
3-hydroxyacyl-CoA dehydrogenase (HADHA)^[4]

Cellular Effect

Cell Line	Type	Value	Description	References
KB	IC₅₀	47.1 μM Compound: 43	Cytotoxicity in human KB cells Cytotoxicity in human KB cells	[PMID: 21504156]

In Vitro

Trimetazidine (1-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induced by oxidation in a certain dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Human umbilical vein endothelial cells (HUVECs)
Concentration:

1 μM,10 μM,100 μM
Incubation Time:

24 hours
Result:

Enhanced the viability of the injured HUVECs induced by oxidation.

In Vivo

Trimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 and 20mg/kg doses significantly raises the seizure-threshold current in the ICES test in the mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss albino male mice (24-35 g)^[4]
Dosage:

5 mg/kg, 10 mg/kg and 20 mg/kg;
10 mL/kg body weight
Administration:

Oral administration ; 1 hour
Result:

In 10 and 20mg/kg doses significantly raised the seizure-threshold current in the ICES test.

Chemical Information

CAS. Nr. 5011-34-7
Appearance Oil
Molecular Weight 266.34
Formel C₁₄H₂₂N₂O₃
Color White to off-white
SMILES

COC1=CC=C(CN2CCNCC2)C(OC)=C1OC
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (19)

All Cell Proliferation/Viability AssayCell Migration/Invasion Assay

Sort by:

Journal Impact Factor

Nat Metab

Cellular Feimin enhances exercise performance by suppressing muscle thermogenesis. [Abstract]

2025 Jan;7(1):84-101. PMID: 39747484
J Adv Res

Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. [Abstract]

2025 Mar 17:S2090-1232(25)00186-9. PMID: 40107354

Trimetazidine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]

OVCAR8-Persister and A2780-Persister cells were pretreated with vehicle or Trimetazidine (TMZ) (100 μM; 24 h) and subsequently treated with various concentrations of paclitaxel (1-1×10⁴ nM; 48 h), after which cell viability was assessed using a CCK-8 assay.

Trimetazidine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]

Trimetazidine (TMZ) (100 μM; 24 h) pretreatment increased the sensitivity of OVCAR8-Persister and A2780-Persister cells to paclitaxel.
Mol Cell

Histone Deacetylase 3 Couples Mitochondria to Drive IL-1β-Dependent Inflammation by Configuring Fatty Acid Oxidation. [Abstract]

2020 Oct 1;80(1):43-58.e7. PMID: 32937100
Adv Sci (Weinh)

OCTN2 Activates a Non-Canonical Carnitine Metabolic Pathway to Promote MASH-HCC Progression and Immunotherapy Resistance. [Abstract]

2026 Jan 21:e17054. PMID: 41566533

Trimetazidine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Jan 21:e17054. [Abstract]

Colony formation assays evaluated the proliferative capacity of MASH‐HCC cells (PA/OA and IL-6/TNF-α/LPS-treated HuH‐7 cells) and non-MASH-HCC cells transfected with vector or OCTN2, with or without Trimetazidine (TMZ) (1 mM).

Trimetazidine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Jan 21:e17054. [Abstract]

The FAO inhibitor Trimetazidine (TMZ) (1 mM) abrogated the enhanced migration and invasion of non-MASH-HCC cells caused by OCTN2 overexpression.

Trimetazidine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Jan 21:e17054. [Abstract]

Wound healing assays evaluated the migration ability of MASH-HCC and non-MASH-HCC cells transfected with vector or OCTN2, with or without Trimetazidine (TMZ) (1 mM) treatment.
Adv Sci (Weinh)

MTFR2-Mediated Fission Drives Fatty Acid and Mitochondrial Co-Transfer from Hepatic Stellate Cells to Tumor Cells Fueling Oncogenesis. [Abstract]

2025 Jun;12(23):e2416419. PMID: 40365837
Sci Adv

Glutamate utilization fuels rapid production of mitochondrial ROS in dendritic cells and drives systemic inflammation during tularemia. [Abstract]

2025 Aug 29;11(35):eadu6271. PMID: 40880474
Acta Pharmacol Sin

Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter. [Abstract]

2022 Oct;43(10):2550-2561. PMID: 35217815
Cell Rep

Nuclear HMGB1 is critical for CD8 T cell IFN-γ production and anti-tumor immunity. [Abstract]

2024 Aug 7;43(8):114591. PMID: 39116204
J Ethnopharmacol

Qiang-Xin 1 formula improves cardiac function and alleviates myocardial injury in lipopolysaccharide-induced septic mice by activating calcium/calmodulin-dependent protein kinase I-mediated mitophagy. [Abstract]

2026 Mar 1:358:121033. PMID: 41397542
J Ethnopharmacol

Integrating UPLC-Q-TOF-MS/MS, feature-based molecular networking, network pharmacology, and molecular docking to investigate the mechanism of Persicae Ramulus against myocardial ischemia. [Abstract]

2026 Feb 28:357:120899. PMID: 41241210
Food Funct

Corn silk extract ameliorates cisplatin-induced cardiac injury by restoring mitochondrial function and suppressing ferroptosis. [Abstract]

2026 May 12;17(9):4090-4109. PMID: 41989386
ACS Appl Nano Mater

2025 Jun 9;8(24).
J Pathol

Hypoxia-induced regional heterogeneity in proliferative vitreoretinopathy: implications for targeted therapies. [Abstract]

2026 Jan;268(1):99-112. PMID: 41215615
Front Biosci (Landmark Ed)

Trimetazidine: Activating AMPK Signal to Ameliorate Coronary Microcirculation Dysfunction after Myocardial Infarction. [Abstract]

2025 Jan 20;30(1):25565. PMID: 39862078
J Pharm Biomed Anal

Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]

2021 Feb 20:195:113870. PMID: 33453569
Anatol J Cardiol

Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. [Abstract]

2019 Nov;22(5):232-239. PMID: 31674935
University of California, Irvine

2026.
bioRxiv

2025 April 10.
Wiad Lek

Potential cardioprotective effect of trimetazidine in mice model of endotoxemia: role of AMPK-Nrf2. [Abstract]

2025;78(1):35-44. PMID: 40023854

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 116.67 mg/mL (438.05 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7546 mL

18.7730 mL

37.5460 mL

5 mM

0.7509 mL

3.7546 mL

7.5092 mL

10 mM

0.3755 mL

1.8773 mL

3.7546 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (477 KB)
- English - EN (477 KB)
- Français - FR (477 KB)
- Deutsch - DE (477 KB)
- Norwegian - NO (477 KB)
- Español - ES (477 KB)
- Swedish - SV (477 KB)
- Italian - IT (477 KB)
- Korean - KR (477 KB)
- Portuguese - PT (477 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shenghu He, et al. Protective effects of trimetazidine against vascular endothelial cell injury induced by oxidation. Journal of Geriatric Cardiology, December 2008 , Vol 5 No 4.

[2]. Chrusciel P, et al. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014 Jun;74(9):971-80. [Content Brief]

[3]. Kantor PF, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86(5):580-8. [Content Brief]

[4]. Hossain F, et al.Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res. 2015 Nov;3(11):1236-47. [Content Brief]

[5]. Jain S, et al. Trimetazidine exerts protection against increasing current electroshock seizure test in mice. Seizure. 2010 Jun;19(5):300-2. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7546 mL	18.7730 mL	37.5460 mL	93.8650 mL
	5 mM	0.7509 mL	3.7546 mL	7.5092 mL	18.7730 mL
	10 mM	0.3755 mL	1.8773 mL	3.7546 mL	9.3865 mL
	15 mM	0.2503 mL	1.2515 mL	2.5031 mL	6.2577 mL
	20 mM	0.1877 mL	0.9386 mL	1.8773 mL	4.6932 mL
	25 mM	0.1502 mL	0.7509 mL	1.5018 mL	3.7546 mL
	30 mM	0.1252 mL	0.6258 mL	1.2515 mL	3.1288 mL
	40 mM	0.0939 mL	0.4693 mL	0.9386 mL	2.3466 mL
	50 mM	0.0751 mL	0.3755 mL	0.7509 mL	1.8773 mL
	60 mM	0.0626 mL	0.3129 mL	0.6258 mL	1.5644 mL
	80 mM	0.0469 mL	0.2347 mL	0.4693 mL	1.1733 mL
	100 mM	0.0375 mL	0.1877 mL	0.3755 mL	0.9386 mL

Keywords

Trimetazidine

19 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Trimetazidine

FDA-Approved Drug Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Trimetazidine

Biologische Aktivität

Chemical Information

Publications (19)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Trimetazidine

FDA-Approved Drug Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Trimetazidine

Biologische Aktivität

Chemical Information

Publications (19)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Trimetazidine Related Classifications

HY-B0968A Related Classifications